Skip to content

A Network-Guided Modular Framework for drug response prediction in acute myeloid leukemia.

Aug 2026 · Computational biology and chemistry · Vol 126 Pt 1, pp. 109355 · 0 citations · 38 references
Medicine

TL;DR

NGM-AML, a modular model predicting ex vivo drug response from BeatAML2 RNA-seq and sensitivity data, achieves mean Pearson and Spearman correlations of 0.324 and 0.326 across drugs, consistent with known AML survival and drug-resistance mechanisms.

Abstract

Drug response prediction in acute myeloid leukemia (AML) is challenged by sample heterogeneity and high-dimensional RNA sequencing profiles. We develop NGM-AML, a modular model predicting ex vivo drug response from BeatAML2 RNA-seq and sensitivity data. After filtering, 306 Waves 1+2 samples (28055 records) serve as training and 173 Waves 3+4 samples (16123 records) as the test set across 111 drugs. Drug targets and AML prior genes are mapped to a PPI network; random walk with restart and community detection construct 45 modules. Per drug, module scores are partitioned into sensitivity and resistance components by their association with the area under the dose-response curve. The results show that NGM-AML achieves mean Pearson and Spearman correlations of 0.324 and 0.326 across drugs, with an MAE of 37.396. Pooling all test records yields a Pearson correlation of 0.703 between predicted and observed AUC. For representative drugs, Pearson correlations reach 0.780 for Venetoclax and 0.631 for Trametinib. Within patients, median Spearman correlation and NDCG@5 are 0.75 and 0.96 for drug ranking. Runtime decreases from 87125.4 s for the raw RNA-seq model to 1102.5 s for NGM-AML. Enriched processes include extracellular matrix adhesion, integrin signaling, and RTK/MAPK pathways, consistent with known AML survival and drug-resistance mechanisms.

View source

Similar papers

Preprint Sep 2026

A Network-Structured Bayesian Hierarchical Model for Sparse Mutation-Drug Response Associations: Application to Cancer Pharmacogenomics

Results show the framework identifies sparse, interpretable, externally supported drug-sensitivity markers while enabling principled investigation of tissue-specific departures from shared effects, as well as improving sensitivity recovery under network-structured signal.

Hammed A. Olayinka, Saheed O. Olayemi · 0 citations
Open access Sep 2026

Identification of Candidate Diagnostic Biomarkers and Construction of an Interpretable Machine-Learning Model for Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a molecularly heterogeneous disease, with considerable variation in molecular abnormalities and gene-expression patterns among patients. This study aimed to identify a compact diagnostic gene signature and develop an interpretable machine-learning model for distinguishing AML from normal...

Shan Liu · 0 citations
Open access Sep 2026

AI‑Driven Multi‑Omics Integrative Model for Predicting Tumor‑Specific Drug Responses

An AI-driven multi-omics model using GDSC, CCLE, DepMap, CTRP, and TCGA data, integrating mutation, copy-number variation, RNA expression, DNA methylation, drug SMILES, and IC50/AUC responses is developed, demonstrating that multi-omics fusion and drug-structure modeling improve prediction stability and support interpr...

Xin-Yuan Kang, Ai-Lin Deng · 0 citations
Open access Sep 2026

Bidirectional network hubs: NT-genes as candidate targets for partial cancer reversal

A quantitative model to predict intervention outcomes in a tumor using gene activation frequencies and two topological metrics: the composed coverage and the fraction of the T-network unreached by the reverse deactivation cascade (U).

Gabriel Gil, Rolando Pérez, Augusto Gonzalez · 0 citations
Open access Aug 2026

TargetPrior: a miRNA-signature embedded evolutionary learning framework for prioritizing drug targets in acute myeloid leukemia

TargetPrior is presented as a computational proof-of-concept for generating prioritized therapeutic hypotheses, rather than as a universal target-discovery solution, and showed stronger early-rank retrieval than network-only and statistical approaches.

Ting-Yu Chen, Shinn-Ying Ho · 0 citations
Open access Sep 2026

Acute Myeloid Leukemia(AML) proteins for in silico drug design using pharmacophore modeling, molecular docking and molecular dynamics simulation

This comprehensive in-silico framework integrates transcriptomic data, network analysis, pharmacophore modeling, and molecular simulations to identify novel biomarkers and drug candidates for AML, providing a foundation for further experimental validation and therapeutic development.

Partho Bosu, Tonmoy Adhikary, A. S. Rafi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.